Safety and Completion Rate of Short‐Course Therapy for Treatment of Latent Tuberculosis Infection
Open Access
- 1 August 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (3), 271-275
- https://doi.org/10.1086/505398
Abstract
Background. Nine months of isoniazid therapy is the recommended regimen for treatment of latent tuberculosis infection, but low completion rates are a serious problem. The search for shorter regimens, compared with the standard isoniazid regimen, is of vital importance. We describe our experience using short-course regimens for the treatment of latent tuberculosis infection. Methods. We conducted a nonrandomized, observational study of 459 patients in a county health department from June 2000 to January 2006. Short-course therapy was defined as pyrazinamide and rifampin taken daily or twice weekly for 2 months or rifampin taken daily for 4–6 months. Conventional therapy consisted of a 9-month regimen of isoniazid. Liver function testing was performed for both groups in accordance with clinical guidelines. Treatment completion and hepatotoxicity (according to the World Health Organization classification) were determined for the short-course and conventional therapy groups. Results. Treatment was completed by 241 (77.7%) of 310 patients in the short-course group and by 98 (65.8%) of 149 patients in the isoniazid group (P = .009). Moderate to severe hepatotoxicity (grades 3 and 4) occurred in 6.1% of patients receiving short-course therapy and in 2.0% of patients receiving isoniazid (P = .09). The hepatotoxicity observed in the short-course group was confined to patients receiving pyrazinamide and rifampin daily and was self limited in all cases after the medications were discontinued. Conclusions. The rate of treatment completion was significantly higher with short-course regimens, compared with the isoniazid regimen. Although the overall risk of hepatotoxicity in patients receiving pyrazinamide and rifampin daily for the treatment of latent tuberculosis infection was higher, liver functions returned to normal after the medications were discontinued.This publication has 14 references indexed in Scilit:
- Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis InfectionClinical Infectious Diseases, 2006
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United StatesAmerican Journal of Respiratory and Critical Care Medicine, 2005
- National Survey to Measure Rates of Liver Injury, Hospitalization, and Death Associated with Rifampin and Pyrazinamide for Latent Tuberculosis InfectionClinical Infectious Diseases, 2005
- Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons*Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2005
- Priorities for the Treatment of Latent Tuberculosis Infection in the United StatesThe New England Journal of Medicine, 2004
- Use of Isoniazid for Latent Tuberculosis Infection in a Public Health ClinicAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003
- Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV InfectionSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2002
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Adherence to Isoniazid Prophylaxis in the HomelessArchives of Internal Medicine, 2000